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ABSTRACT
The aim of this study was to observe the impact of the mammalian sterile 20-like kinase 1-c-
Jun N-terminal kinase (MST1-JNK) signaling pathway on apoptosis in colorectal cancer (CRC)
cells induced by Taurine (Tau). Caco-2 and SW620 cells transfected with p-enhanced green
fluorescent protein (EGFP)-MST1 or short interfering RNA (siRNA)-MST1 were treated with Tau
for 48 h. Apoptosis was detected by flow cytometry, and the levels of MST1 and JNK were
detected by western blotting. Compared with the control group, 80 mM Tau could signifi-
cantly induce apoptosis of CRC cells, and the apoptotic rate increased with increasing Tau
concentration (P < 0.01). Meanwhile, the protein levels of MST1 and phosphorylated (p)-JNK
in Caco-2 cells increased significantly (P < 0.01). The apoptotic rate of the p-EGFP-MST1
plasmid-transfected cancer cells was significantly higher than that of the control group
(P < 0.05); however, the apoptotic rate of the p-EGFP-MST1+Tau group was increased further
(P < 0.01). Silencing the MST1 gene could decrease the apoptotic rate of cancer cells, and Tau
treatment could reverse this decrease. Blocking the JNK signaling pathway significantly
reduced the Tau-induced apoptotic rate of CRC cells. Thus, the MST1-JNK pathway plays an
important role in Tau-induced apoptosis of CRC cells.
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1. Introduction
Colorectal cancer (CRC) is one of the most common
malignancies in humans [1]. The International Agency
for Research on Cancer (IARC) reported that the inci-
dence of CRC ranks third among global malignancies,
and mortality rate due to CRC has risen to fourth for
malignant tumors [1]. Therefore, the prevention and
treatment of CRC has become a hotspot in cancer
control research. Presently, research on tumor preven-
tion and treatment is directed toward exploring the
association between abnormal cell signaling path-
ways and the occurrence and development of tumors.
The Hippo pathway is a hotspot for studying the
occurrence, development, and targeted therapy for
CRC. The mammalian sterile 20-like kinase 1 (MST1/
2) is a core member of the Hippo signaling pathway,
and its abnormality is commonly observed in CRC [2]
and liver cancer [3]. Many studies have confirmed the
importance of the MST-Hippo pathway in the occur-
rence and development of CRC [4,5]. Inhibitors target-
ing this pathway play important roles in preventing
and treating CRC. Other studies have shown that the
c-Jun N-terminal kinase (JNK) signaling pathway is
involved in cell proliferation and differentiation. Its
dysfunction can cause ischemia/reperfusion injury
[6], diabetes [7], or tumors [8]. Thus, the JNK signaling
pathway has become a potential clinical molecular
therapeutic target.
Taurine (Tau) is an endogenous cell protective
agent. Recent studies have found that it has good
anti-tumor effects [9–14]. For example, Tau can inhibit
the in vitro invasion and migration of breast cancer
cells and has a better therapeutic effect against
methylbenzanthracene (DMBA)-induced breast cancer
[11,12]. Our previous studies have shown that Tau can
inhibit the apoptosis of cardiomyocytes subjected to
ischemia/reperfusion [15] and can induce (or pro-
mote) apoptosis in colon cancer [10], breast cancer
[13,14], or liver cancer cells [12]. This effect is achieved
by up-regulating the expression of BCL-2, PMA, and
P53, while down-regulating the expression of BCL-2.
Furthermore, Tau has better inhibitory effect toward
the proliferation of P53−/− tumor cells than toward
P53+/+ tumor cells [10], indicating that the Tau-
induced apoptosis of cancer cells is not only related
to the mitochondrial apoptotic pathway but also
involves other apoptotic signaling pathways. Recent
studies have found that MST1 [16] and JNK [17] play
important roles in the occurrence and development of
colon cancer; however, whether the MST1-JNK
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signaling pathway is involved in the Tau-induced
apoptosis of CRC cells has not been reported till
date. In the present study, the CRC cell lines, SW620
and Caco-2, were used as the study subjects, in which
the expression of the MST1 gene was regulated and
the JNK pathway was inhibited to investigate the
effect of the MST1-JNK signaling pathway in Tau-
induced apoptosis of CRC cells. This allowed us to
explore the molecular mechanism underlying the inhi-
bition of the growth of CRC by Tau, thus, providing
experimental evidence for the clinical application of
Tau to treat CRC.
2. Materials and methods
2.1. Cell line and culture
The human CRC cells Caco-2 and SW620 (purchased
from Cell Bank of Type Culture Collection Committee,
CAS) were cultured in the complete Dulbecco’s modi-
fied eagle’s medium (DMEM) (Hyclone) containing 10%
fetal bovine serum (FBS) (TransGen Biotech Co. Ltd.) at
37°C under 5% CO2 conditions.
2.2. MTS colorimetry
The cells in the logarithmic growth phase were ran-
domly divided into eight groups [Control (CON), Tau
10 mM (T10), Tau 20 mM (T20), Tau 40 mM (T40), Tau
80 mM (T80), Tau 160 mM (T160), Tau 320 mM (T320),
and DDP 5 μg/mL (DDP)] and seeded into culture
plates with appropriate amount of sterile phosphate-
buffered saline (PBS). The cells were incubated with
the aforementioned factors for 24, 48, and 72 h,
respectively, and then 20 μl/well Cell Titer 96®
AQueous One Solution Reagent (containing3-(4,5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-
(4-sulfophenyl)-2H-tetrazolium) (MTS)) was added; the
samples were incubated for another 4 h. The OD value
of each well was measured at 490 nm using a micro-
plate reader to plot the cell growth curve.
Proliferation inhibition rate (%) = (1-OD value of test
group/OD value of CON) × 100%.
2.3. Flow cytometry
The cells in the logarithmic growth phase were ran-
domly grouped and treated with different methods.
Cells (1–5 × 105) were then collected, and 500 μl of
Binding Buffer was added to suspend the cells.
Annexin V-FITC (5 μl; BestBio, Shanghai, China) was
then added to the cells, vortexed, and 5 μl of propi-
dium iodide was added, mixed evenly, and incubated
for 5–15 min at room temperature in the dark.
Apoptotic cells were then detected using a
FACScalibur flow cytometer (Becton Dickinson, USA).
2.4. Hoechst 33342 staining
The cells in the logarithmic growth phase were ran-
domly grouped and treated with different methods.
The cells were placed in CO2 incubator for 48 h at 37°
C. After incubation, the cells were washed with PBS
three times. The solution of Hoechst 33342 was added
to the cells, and after 20 min of staining the cells were
observed under a fluorescence microscope at
200 × magnification. Apoptosis rate (%) = apoptotic
cells/total cells × 100%.
2.5. Plasmid vector and transfection
The plasmid p-EGFP-MST1, which overexpresses the
enhanced green fluorescent protein (EGFP) fused to
the human wild-type MST1, and the empty vector
p-EGFP-NC, were synthesized and characterized by
Chuanming Xu in our laboratory.
The recombinant plasmid, pEGFP-MST1, and the
empty vector, pEGFP-NC, (Clontech, Mountain View,
USA) were treated with the PolyJet™ in vitro DNA
transfection reagent (Cat. # SL100688; SignaGen,
Rockville, USA) and transfected into SW480 cells.
First, the SW480 cells were cultured in 6-well plate
still 60%–70% confluence was achieved. The original
medium was discarded, and 900 ml of fresh com-
plete medium was added to each well; the cells
were cultured for another 30–60 min. Thereafter,
50 μl of transfection solution was added and gently
mixed; the cells were cultured at 37°C under 5%
CO2 for 5 h. The medium was then replaced with
10% FBS-containing DMEM (Hyclone), and the cells
were incubated for another 24–48 h. The transfec-
tion efficiency was then determined, and the cells
were photographed.
Preparation of the transfection solution: for solu-
tion A, 1 μg of plasmid was dissolved in 50 μl of
serum-free DMEM medium and pipetted three to
four times; for solution B, 3 μl of PolyJet™ reagent
was dissolved in 50 μl of serum-free DMEM medium
and pipetted three to times; and for solution C
(transfection solution), solution B was added to
solution A and rapidly pipetted three to four
times, and the cells were cultured for 15 min at
room temperature.
Grouping and treatment for pEGFP-MST1 transfection:
(1) Control (CON): the cells were cultured with FBS-free
DMEM for 6 h, and the mediumwas then changed to the
complete medium; the cells were cultured for another
48 h. (2) In the p-EGFP-NC group, the cells were trans-
fected with the empty vector, p-EGFP-NC, and cultured
for 48 h. (3) In the p-EGFP-MST1 group, the cells were
transfected with plasmid, p-EGFP-MST1, and cultured for
48 h. (4) In the p-EGFP-MST1+ Tau group, the cells were
transfected with plasmid, p-EGFP-MST1, on the second
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day of seeding, cultured for 24 h, 160 mmol/l of Tau was
then added, and the cells were cultured for another 24 h.
Grouping and treatment for siRNA-MST1 transfec-
tion: (1) CON: the cells were cultured with FBS-free
DMEM for 6 h, and medium was then changed to the
complete medium; the cells were cultured for another
48 h. (2) In the siRNA-NC group, the cells were trans-
fected with the control short interfering RNA (siRNA-
NC) and cultured for 48 h. (3) In the siRNA-MST1
group, the cells were transfected with siRNA-MST1
and cultured for 48 h. (4) In the siRNA-MST1+Tau
group, the cells were transfected with siRNA-MST1
on the second day of seeding, cultured for 24 h,
160 mmol/l of Tau was added, and the cells were
cultured for another 24 h.
2.6. Western blotting
Total proteins were extracted from the cells and dena-
tured; the extracted protein (30 μg/well protein) was
subjected to SDS-PAGE. The proteins were then trans-
ferred onto a polyvinylidene difluoride membrane
(PVDF, Millipore, USA) by the wet transfer method. The
membrane was then incubated with an MST1 monoclo-
nal antibody (ab51134, Abcam), JNK1 polyclonal antibo-
dies (ab134466, Abcam), phosphorylated (p)-JNK
polyclonal antibodies (ab18680, Abcam), BAX polyclonal
antibodies (50599-2-lg, SAB), and BCL-2 polyclonal anti-
bodies (#21059, SAB) (1:200) overnight at 4°C. The mem-
brane was then incubated with the horseradish
peroxidase-conjugated secondary antibodies (1:2000)
Figure 1. Impact of Tau on apoptosis of Caco-2 and SW620. After Caco-2 and SW620 were added varying levels of Tau and DDP
(5 μg/mL) for 48 h, respectively, Tau with concentration more than 80 mM can significantly induce the apoptosis of Caco-2 and
SW620. **P < 0.01 vs. Control.
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for 1.5 h; the ECL immunoassay was then performed in
the dark. The immunoreactive protein bands were
scanned using the Image-Pro Plus 6.0 image analysis soft-
ware and subjected to semi-quantitative analysis using
antibodies against β-actin (AF7018, Santa Cruz) as the
control.
2.7. Impact of blocking the JNK pathway on the
levels of apoptosis-related proteins
Cells in the logarithmic growth phase were randomly
divided into five groups and treated with different
methods:
(1) CON: The original medium was changed to fresh
complete medium on the second day of plate
seeding, and the cells were cultured for 48 h.
(2) DMSO group: The cells were cultured in DMSO
(at the same final concentration of DMSO as that
in the JNK group) for 1 h, and then the DMSO
was replaced with fresh culture medium; the
cells were cultured for another 48 h.
(3) JNK group: The cells were incubated with the JNK
inhibitor, SP600125(final concentration: 25 μM in
DMSO), for 1 h and then the inhibitor containing
mediumwas replacedwith fresh culturemedium;
the cells were cultured for another 48 h.
(4) SP600125+Tau group: The cells were culturedwith
the JNK inhibitor SP600125 (final concentration:
25 μM in DMSO) for 1 h, and then SP600125
containing medium was removed; the cells were
cultured with Tau (final concentration:160mM) for
another 48 h.
(5) SP600125 + p-EGFP-MST1 group: The p-EGFP-
MST1-transfected CRC cells were cultured with
the JNK inhibitor SP600125 (final concentration:
25 μM in DMSO) for 1 h, and then the medium
containing SP600125 was removed; the cells
were cultured for another 48 h.
From all five groups, the cells were collected and
the total proteins were extracted for protein detection.
2.8. Statistical analysis
SPSS19.0 statistical software was used to compare the
parameters among different groups using one-way
analysis of variance (ANOVA); the pairwise comparison
of inter-group parameters used the q test. P < 0.05
was considered statistically significant.
3. Results
3.1. Impact of Tau on proliferation and apoptosis
of CRCs
Figure 1 shows that after Caco-2 and SW620 cells were
treatedwith Tau (0, 80, 160, and 320mM) andDDP (5 μg/
mL) for 48 h, Tau concentrations higher than 80 mM
significantly induced apoptosis in Caco-2 and SW620
Figure 2. Impact of Tau on Mst1, JNK, and p-JNK proteins in Caco-2 and SW620. (A) In Caco-2, the protein expressions of Mst1
and p-JNK increased gradually with the increase of the Tau concentration. (B) In SW620, Tau had no significant impact on the
protein expressions of Mst1, JNK, and p-JNK in SW620. **P < 0.01 and *P < 0.05 vs. Control.
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cells. Compared with that in the CON group, the apop-
tosis rate in the two types of cells increased gradually
with increasing Tau concentration, and the differences
were all statistically significant (P < 0.01).
3.2. Impact of Tau on MST1, JNK, and p-JNK
proteins in CRC cells
Figure 2 shows that in Caco-2 cells, the protein levels of
MST1 and p-JNK increased gradually as the Tau
concentration increased (P < 0.01); however, there was
no significant difference in the level of JNK. High concen-
trations of Tau had no significant impact on the protein
levels of MST1, JNK, and p-JNK in SW620 cells (P > 0.05).
3.3. Impact of MST1 transfection on Tau-
regulated proliferation and apoptosis of CRC cells
The MST1-transfected Caco-2 and SW620 cells were
treated with Tau (160 mM) for 48 h, and the impact of
Figure 3. Impact of Mst1 and Tau (160 mM) on proliferation and apoptosis of Caco-2 and SW620. The high expression of Mst1
alone or in combination with Tau can greatly improve the proliferation inhibitory (A) and apoptosis rate (B, C) in both Caco-2
and SW620. The Q2 (AnnexinV+ PI+) indicates the late stage for cell death and Q3 (Annexin+PI-) presents the early stage for
cell. **P < 0.01 vs. group p-EGFP-NC; #P < 0.05 vs. group p-EGFP-Mst1.
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Tau on the proliferation and apoptosis of these two
CRC cell lines was observed. Figure 3 shows that the
proliferation inhibition rate of the two cells after MST1
transfection was significantly increased compared
with that of the p-EGFP-NC group, and the differences
were statistically significant (P < 0.01). Compared with
that in the p-EGFP-NC group, the proliferation inhibi-
tion rate in the p-EGFP-MST1+Tau group for both
these two cell types was significantly increased
(P < 0.01), and was much higher than that in the
cells only transfected with MST1 (P < 0.05). The results
showed that high expression of MST1 gene could
inhibit the proliferation of CRC cells, and the treat-
ment with Tau could further inhibit their proliferation
(Figure 3(a)).
The MST1-transfected Caco-2 and SW620 cells were
treated with Tau for 48 h and then apoptosis was
determined. Figure 3(b), (c) show that the apoptotic
rates of the two cell lines after MST1 transfection were
significantly increased compared with those in the
p-EGFP-NC group (P < 0.01). The total apoptotic rates
in the p-EGFP-MST1+Tau groups for the two cell lines
were further significantly increased (P < 0.05). It can be
seen from Figure 4 that the nuclei in the control group
and the p-EGFP-NC group are light blue with intact cell
morphology, but the nuclei in the p-EGFP-Mst1 group
and the p-EGFP-Mst1+Tau group are darker blue with
broken cells and visible apoptotic bodies. The results
showed that the apoptosis in the p-EGFP-Mst1 group
was significantly higher than the p-EGFP-NC group, and
the increase of apoptosis was more significant in the
p-EGFP-Mst1+Tau group. (P < 0.01)；Compared with
the p-EGFP-Mst1 group, the apoptosis rate in the
p-EGFP-Mst1+ Tau group also increased significantly
Figure 4. Fluorescence microscopic (at 200× magnification) study of apoptosis in both Caco-2 and SW620 cells using Hoechst
33342 staining dye. The high expression of Mst1 alone or in combination with Tau can greatly improve the apoptosis rate in
both Caco-2 and SW620. **P < 0.01 vs. group p-EGFP-NC; ##P < 0.01 vs. group p-EGFP-Mst1.
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(P < 0.01). The results showed that MST1 can promote
the apoptosis of CRC cells, which can be further
increased by the combined effect of MST1 and Tau;
therefore, MST1 and Tau have synergistic effects on
apoptosis in CRC cells.
3.4. Impact of MST1 and tau on JNK, p-JNK, BAX,
and BCL-2 proteins in CRC cells
Figure 5 shows that compared with those in the CON
group, the protein levels ofMST1, JNK, p-JNK, and BAX
in Caco-2 cells in the p-EGFP-MST1 group were sig-
nificantly upregulated (P < 0.01); however, the level of
BCL-2 was downregulated (P < 0.01). In the p-EGFP-
MST1+ Tau group, for the Caco-2 cells, the levels of
JNK, p-JNK, and BAX proteins in group were more
significantly upregulated (P < 0.01), while that of
BCL-2 was significantly downregulated (P < 0.01).
Similar results were also observed for the SW620
cells (Figure 5).
3.5. Impact of silencing MST1 on Tau-induced
apoptosis of Caco-2 and SW620 cells
Figure 6 shows that the apoptotic rates of the two cell
lines after silencing the MST1 gene decreased signifi-
cantly compared with those of the cells of the siRNA-
NC group (P < 0.01). The apoptotic rates for both cell
lines in thep-EGFP-MST1+Tau group were significantly
increased compared with those in the siRNA-NC
group (P < 0.05); the apoptotic rates further signifi-
cantly increased compared with those for the two cell
lines in the siRNA-MST1 group (P < 0.01). Figure 7
shows that compared with the siRNA-NC group, the
apoptosis is significantly decreased in the siRNA-Mst1
group, but the apoptosis is significantly increased in
the siRNA-Mst1+Tau group (P < 0.01); compared to
the siRNA-Mst1 group, the siRNA-Mst1+Tau group
shows more significantly increased apoptosis rate
(P < 0.01). The results showed that downregulating
the MST1 gene could inhibit apoptosis in CRC cells,
but Tau treatment could significantly promote
apoptosis.
3.6. Impact of silencing MST1 on JNK, BAX BCL-2,
and p-JNK proteins in tau-regulated CRC cells
The impact of silencing MST1 on JNK, BAX BCL-2, and
p-JNK protein levels in Tau-regulated Caco-2 and
SW620 cells was tested by western blotting
(Figure 8). After silencing the MST1 gene, the BAX
protein level was significantly downregulated com-
pared with that in the CON group (P < 0.01); however,
the BCL-2 protein level was significantly upregulated
(P < 0.05); the JNK, p-JNK, and BAX levels in SW620
cells were significantly downregulated (P < 0.01);
however, the level of BCL-2 was significantly regu-
lated (P < 0.01). In Caco-2 cells (Figure 8(a)), the
level of BAX in the siRNA-MST1+Tau group was sig-
nificantly higher than that in the CON or siRNA-MST1
groups (P < 0.01); however, the level of BCL-2 was
significantly decreased (P < 0.01). In SW620 cells
(Figure 8(b)), the levels of JNK (P < 0.01), p-JNK
(P < 0.01), and BCL-2 in the siRNA-MST1+Tau group
Figure 5. Impact of Mst1 and Tau on JNK, p-JNK, Bax, and Bcl-2 proteins in CRCs. The protein levels of Mst1, JNK, p-JNK, and Bax
of Caco-2 and SW60 were significantly upregulated but Bcl-2 was downregulated in both group p-EGFP-Mst1 and p-EGFP-Mst1
+ Tau. *P < 0.05, **P < 0.01 vs group Control or p-EGFP-NC; #P < 0.05, ##P < 0.01 vs group p-EGFP-Mst1.
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were significantly reduced, while the BAX level was
significantly increased compared with that in the CON
group (P < 0.01). Compared with those in the siRNA-
MST1 group, the levels of JNK, p-JNK, and BCL-2 in the
siRNA-MST1+Tau were significantly reduced, while the
BAX level was significantly increased (P < 0.01).
3.7. Impact of the JNK Inhibitor SP600125 and
Tau on JNK, BAX BCL-2, and p-JNK proteins in
Caco-2 and SW620 cells
The impact of SP600125 alone and of SP600125 in
combination with Tau or p-EGFP-MST1, on the levels
of MST1, JNK, p-JNK, BAX, and BCL-2 proteins in the two
types of CRC cells, were analyzed by western blotting.
Figure 9 shows that compared with their levels in the
DMSO group, the levels of JNK, p-JNK, and BAX in both
types of SP600125-treated cells were significantly
decreased; however, the level of BCL-2 was significantly
increased (P < 0.05). In contrast, the level of MST1 was
not significantly different. Compared with those in the
SP600125 group, the levels of MST1, JNK, p-JNK, and
BAX in Caco-2 cells in the SP600125+Tau group were
significantly increased (Figure 9(a)) (P < 0.01); however,
the level of BCL-2 was significantly decreased (P < 0.01).
The levels of BCL1 and JNK in SW620 cells (Figure 9(b))
Figure 6. Impact of silencing Mst1 on Tau-promoted apoptosis of CRCs. The apoptotic rates of the Caco-2 and SW620 were
significantly decreased in group siRNA-Mst1 but increased in group siRNA-Mst1+ Tau. The Q2 (AnnexinV+ PI+) indicates the late
stage for cell death and Q3 (Annexin+ PI-) presents the early stage for cell. *P < 0.05, **P < 0.01 vs group Control or siRNA-NC;
##P < 0.01 vs group siRNA-Mst1.
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did not show a significant change; however, the levels
of p-JNK and BAX were significantly increased (P < 0.01)
while the level of BCL-2 was significantly decreased
(P < 0.01).
4. Discussion
Tau (β-aminoethanesulfonic acid, C2H7NO3S), also
known as cholic acid, is the most abundant β-amino
acid in vivo. It normally exists in tissues and cells in
the free form, does not participate in protein synth-
esis, and is an important endogenous anti-injury sub-
stance in the human body [18,19]. Recent studies
have shown that Tau is involved in the most impor-
tant pathway related to tumor metabolism [20,21].
The anti-tumor mechanism of Tau is mainly related
to Tau-induced apoptosis, synergism, and attenuation
[9–13], via regulating the expression of key genes at
both the transcriptional and translational levels. For
example, Zhang et al. showed that Tau prompted the
transcription and translation of the PUMA gene in HT-
29 colorectal cancer cells [10], and Sorensen et al.
indicated that Tau increases LRRC8A expression in
wild-type A2780 cells [22]; however, the specific
mechanisms underlying these effects have not been
elucidated. In the present study, we investigated the
impact of Tau on apoptosis in CRC cells by changing
the expression of MST1 gene or inhibiting the JNK
pathway, aiming to investigate the roles of the
MST1-JNK signaling pathway in the Tau-induced
apoptosis in CRC cells. The results confirmed that
the MST1-JNK pathway plays an important role in
Tau-induced apoptosis of CRC cells; Tau at concentra-
tions greater than 80 mM could significantly induce
apoptosis in Caco-2 and SW620 cells (P < 0.01), and
the protein levels of MST1 and p-JNK also increased
gradually with increasing Tau concentrations
Figure 7. Fluorescence microscopic (at 400× magnification) study of apoptosis in both Caco-2 and SW620 cells using Hoechst
33342 staining dye. The apoptotic rates of the Caco-2 and SW620 were significantly decreased in group siRNA-Mst1 but
increased in group siRNA-Mst1+ Tau. **P < 0.01 vs group Control or siRNA-NC; ##P < 0.01 vs group siRNA-Mst1.
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(P < 0.01). Overexpression of the MST1 gene could
promote apoptosis in CRC cells and inhibit their pro-
liferation. These effects were further enhanced when
MST1 overexpression occurred in combination with
Tau treatment (Figure 3). In contrast, silencing the
MST1 gene significantly reduced the apoptosis pro-
moting and cancer cell proliferation inhibiting effects
of Tau; the level of BAX significantly decreased
Figure 8. Impact of silencing Mst1 on apoptosis-related proteins in Tau-regulated CRCs. In contrast to group siRNA-Mst1, the
protein expression of Bax increased and Bcl-2 decreased significantly in group siRNA-Mst1+ Tau in both Caco-2 and SW620.
*P < 0.05, **P < 0.01 vs group Control or siRNA-NC; #P < 0.05, ##P < 0.01 vs group siRNA-Mst1.
Figure 9. Impact of JNK inhibitor on apoptosis-related proteins in Tau-regulated CRCs. Compared to the group SP600125, the
expressions of JNK, p-JNK, and Bax were increased and Bcl-2 decreased in group SP600125+ Tau and SP600125 + p-EGFP-Mst1
of Caco-2 and SW620. **P < 0.01 vs group DMSO or Control; ##P < 0.01 vs SP600125.
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(P < 0.01), but the level of BCL-2 significantly
increased (P < 0.05). Our results showed that Tau
could induce apoptosis in CRC cells and inhibit their
proliferation, and the mechanism underlying these
effects involves increasing the level of MST1 in CRC
cells, which then upregulates the expression of pro-
apoptotic proteins, such as BAX, but downregulates
the expression of anti-apoptotic proteins, such as BCL-
2. Recent studies have found that the expression
levels of MST1 and YAP1 in human colon cancer tissue
are significantly higher than those in the adjacent
tissues [23,24]. In human primary colon cancer, ade-
nomatous colonic polyposis, or mouse multiple intest-
inal tumor, the expression of YAP is upregulated,
which could also promote the growth of transplanted
tumors in a mouse model. Therefore, the MST-Hippo
pathway plays an important role in the occurrence
and development of CRC, and inhibitors against this
pathway have become important targets for research
to prevent and treat colon cancer [4,5].
JNK, also known as stress-activated kinase (SAPK), is
one of the major members of the mitogen-activated
protein kinase (MAPK) superfamily. JNK is related to the
occurrence and development of tumors [25], ischemia-
reperfusion (I/R) injury [26], immune inflammatory
response [27], and other diseases. JNK is mainly loca-
lized in the cytoplasm. When activated, partially acti-
vated JNK translocates into the nucleus to activate
intranuclear transcription factors, such as c-JUN, ATF2,
or p53, by phosphorylation [28–30], thus, enhancing
the expression of downstream apoptosis-related
genes and promoting apoptosis. The results of the
present study showed that Tau could promote the
expression of JNK and its phosphorylation in Caco-2
cells, and increase apoptosis of CRC cells by activating
the MST1-JNK pathway. When the activity of JNK was
inhibited, Tau-induced apoptosis of CRC cells was alle-
viated. In addition, activated JNK can also phosphory-
late many proteins of the BCL-2 family, inhibiting the
anti-apoptotic activity of BCL-2 and BCL-XL, and pro-
moting the activation of BAX, BIM, and PUMA, thus,
leading to mitochondrial dysfunction, the release of
cytochrome C, and apoptosis [31]. Ura et al. [32]
reported that JNK not only participates in MST1-
induced apoptosis, but can also regulate the activity
of MST1 via feedback mechanism, resulting in promo-
tion of apoptosis [33]. Thus, MST1 activates the JNK
signaling pathway when it promotes apoptosis and in
turn, the JNK signaling pathway also plays an important
role in the proapoptotic effect of MST1. Strano et al. [34]
considered that the occurrence of tumors is the conse-
quence of multiple signaling pathways, among which
the Hippo signaling pathway and the p53 apoptotic
signaling pathway have certain functional connections.
In adrenal pheochromocytoma PC12 cells, YAP is phos-
phorylated at serine 127, prompting YAP to enter the
nucleus and act with protein p73 of the p53 family [35].
p73 then activates the apoptosis-related protein, PUMA,
in the cytoplasm in a transcription-dependent manner,
which, in turn, promotes the release of mitochondrial
cytochrome C, leadingto apoptosis [36]. Therefore, we
hypothesized that the Tau-induced apoptosis of CRC
cells might be the consequence of the combination of
effects mediated by the MST1-JNK signaling pathway,
the MST1-Hippo pathway, the p53 pathway, and the
PUMA-mediated mitochondrial apoptotic signaling
pathway. However, this study did not specifically inves-
tigate all these aspects, and further studies are under-
way to test this hypothesis.
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